Skip to main content

Rydym wedi cadw rhai ffeiliau o'r enw cwcis ar eich dyfais. Y cwcis hyn yw:

  • Hanfodol ar gyfer y safle i weithio
  • Helpu i wella ein gwefan drwy gasglu ac adrodd gwybodaeth am sut rydych chi'n ei defnyddio

Hoffem hefyd arbed rhai cwcis i helpu i deilwra cyfathrebu.

BETA
Rydych yn edrych ar fersiwn wedi'i ddiweddaru o'r gwasanaeth hwn - bydd eich adborth yn ein helpu i'w wella.

Hysbysiad Gwybodaeth Ymlaen Llaw (PIN)

NP49425 Generic and Biosimilar Transition Medicines

  • Cyhoeddwyd gyntaf: 11 Awst 2025
  • Wedi'i addasu ddiwethaf: 11 Awst 2025
  • Cofnodi Diddordeb

     

  • Efallai na fydd y ffeil hon yn gwbl hygyrch.

  •  

Eicon Gwybodaeth

Nid yw'r prynwr yn defnyddio'r wefan hon i weinyddu'r hysbysiad.

I gofnodi eich diddordeb neu gael gwybodaeth neu ddogfennau ychwanegol, darllenwch y cyfarwyddiadau yn Nhestun Llawn yr Hysbysiad. (NODER: Nid oes angen ymateb i Hysbysiadau Dyfarnu Contractau a Hysbysiadau Gwybodaeth Ymlaen Llaw fel arfer)

Cynnwys

Crynodeb

OCID:
ocds-h6vhtk-0581ea
Cyhoeddwyd gan:
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
ID Awudurdod:
AA84556
Dyddiad cyhoeddi:
11 Awst 2025
Dyddiad Cau:
-
Math o hysbysiad:
Hysbysiad Gwybodaeth Ymlaen Llaw (PIN)
Mae ganddo ddogfennau:
Nac Ydi
Wedi SPD:
Nac Ydi
Mae ganddo gynllun lleihau carbon:
AMH

Crynodeb

The Authority seeks to establish a Framework Agreement covering medicines that are imminently approaching or have already reached Loss of Exclusivity (LoE).

The range of medicines under consideration for inclusion in the Framework Agreement are listed below (subject to removal or replacement due to a continually shifting litigation landscape):

- Apremilast 30mg tablets

- Axitinib 1mg tablets

- Axitinib 3mg tablets

- Axitinib 5mg tablets

- Axitinib 7mg tablets

- Betaine oral powder

- Denosumab 120mg/1.7ml solution for injection vials

- Denosumab 120mg/1ml solution for injection pre-filled syringes

- Denosumab 60mg/1ml solution for injection pre-filled syringes

- Eltrombopag 25mg oral powder sachets sugar free

- Eltrombopag 25mg tablets

- Eltrombopag 50mg tablets

- Eltrombopag 75mg tablets

- Ferric carboxymaltose 100mg/2ml dispersion for injection vials

- Ferric carboxymaltose 1g/20ml dispersion for injection vials

- Ferric carboxymaltose 500mg/10ml dispersion for injection vials

- Fluticasone furoate 27.5micrograms/dose nasal spray

- Fluticasone propionate 50micrograms/dose / Azelastine 137micrograms/dose nasal spray

- Generic Otezla tablets treatment initiation pack

- Generic Sustanon 250mg/1ml solution for injection ampoules

- Golimumab 100mg/1ml solution for injection pre-filled disposable devices

- Golimumab 50mg/0.5ml solution for injection pre-filled disposable devices

- Golimumab 50mg/0.5ml solution for injection pre-filled syringes

- Lanreotide 120mg/0.5ml solution for injection pre-filled syringes

- Lanreotide 90mg/0.5ml solution for injection pre-filled syringes

- Lanreotide 60mg/0.5ml solution for injection pre-filled syringes

- Mesalazine 1.5g gastro-resistant modified-release granules sachets sugar free

- Mesalazine 1.6g gastro-resistant tablets

- Mesalazine 1g gastro-resistant modified-release granules sachets sugar free

- Mesalazine 1g modified-release granules sachets sugar free

- Mesalazine 1g modified-release tablets

- Mesalazine 1g suppositories

- Mesalazine 1g/100ml enema

- Mesalazine 1g/application foam enema

- Mesalazine 250mg gastro-resistant tablets

- Mesalazine 2g modified-release granules sachets sugar free

- Mesalazine 2g/59ml enema

- Mesalazine 400mg gastro-resistant tablets

- Mesalazine 4g modified-release granules sachets sugar free

- Mesalazine 500mg gastro-resistant modified-release granules sachets sugar free

- Mesalazine 500mg gastro-resistant tablets

- Mesalazine 500mg suppositories

- Mesalazine 800mg gastro-resistant tablets

- Nilotinib 150mg capsules

- Nilotinib 200mg capsules

- Nilotinib 50mg capsules

- Nintedanib 100mg capsules

- Nintedanib 150mg capsules

- Omalizumab 150mg/1ml solution for injection pre-filled syringes

- Omalizumab 75mg/0.5ml solution for injection pre-filled syringes

- Omalizumab 300mg/2ml solution for injection pre-filled disposable devices

- Omalizumab 300mg/2ml solution for injection pre-filled syringes

- Pazopanib 200mg tablets

- Pazopanib 400mg tablets

- Perampanel 10mg tablets

- Perampanel 12mg tablets

- Perampanel 2mg tablets

- Perampanel 4mg tablets

- Perampanel 500micrograms/ml oral suspension sugar free

- Perampanel 6mg tablets

- Perampanel 8mg tablets

- Pertuzumab 420mg/14ml solution for infusion vials 1 vial

- Testosterone undecanoate 1g/4ml solution for injection ampoules

- Testosterone undecanoate 1g/4ml solution for injection vials

- Ticagrelor 60mg tablets

- Ticagrelor 90mg orodispersible tablets sugar free

- Ticagrelor 90mg tablets

- Tocilizumab 162mg/0.9ml solution for injection pre-filled disposable devices

- Tocilizumab 162mg/0.9ml solu

Testun llawn y rhybydd

Hysbysiad gwybodaeth ymlaen llaw

Hysbysiad gwybodaeth ymlaen llaw yn unig yw hwn

Adran I: Endid contractio

I.1) Enw a chyfeiriad

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

1 South Gyle Crescent

Edinburgh

EH12 9EB

UK

Person cyswllt: Cameron Wright

Ffôn: +44 1312756000

E-bost: cameron.wright@nhs.scot

NUTS: UKM

Cyfeiriad(au) rhyngrwyd

Prif gyfeiriad: http://www.nss.nhs.scot/browse/procurement-and-logistics

Cyfeiriad proffil y prynwr: https://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA11883

I.2) Caffael ar y cyd

Caiff y contract ei ddyfarnu gan gorff prynu canolog

I.3) Cyfathrebu

Gellir cael gwybodaeth ychwanegol o'r cyfeiriad uchod


I.4) Y math o awdurdod contractio

Corff a lywodraethir gan gyfraith gyhoeddus

I.5) Prif weithgaredd

Iechyd

Adran II: Gwrthrych

II.1) Cwmpas y caffaeliad

II.1.1) Teitl

NP49425 Generic and Biosimilar Transition Medicines

II.1.2) Prif god CPV

33600000

 

II.1.3) Y math o gontract

Cyflenwadau

II.1.4) Disgrifiad byr

The Authority seeks to establish a Framework Agreement covering medicines that are imminently approaching or have already reached Loss of Exclusivity (LoE).

The range of medicines under consideration for inclusion in the Framework Agreement are listed below (subject to removal or replacement due to a continually shifting litigation landscape):

- Apremilast 30mg tablets

- Axitinib 1mg tablets

- Axitinib 3mg tablets

- Axitinib 5mg tablets

- Axitinib 7mg tablets

- Betaine oral powder

- Denosumab 120mg/1.7ml solution for injection vials

- Denosumab 120mg/1ml solution for injection pre-filled syringes

- Denosumab 60mg/1ml solution for injection pre-filled syringes

- Eltrombopag 25mg oral powder sachets sugar free

- Eltrombopag 25mg tablets

- Eltrombopag 50mg tablets

- Eltrombopag 75mg tablets

- Ferric carboxymaltose 100mg/2ml dispersion for injection vials

- Ferric carboxymaltose 1g/20ml dispersion for injection vials

- Ferric carboxymaltose 500mg/10ml dispersion for injection vials

- Fluticasone furoate 27.5micrograms/dose nasal spray

- Fluticasone propionate 50micrograms/dose / Azelastine 137micrograms/dose nasal spray

- Generic Otezla tablets treatment initiation pack

- Generic Sustanon 250mg/1ml solution for injection ampoules

- Golimumab 100mg/1ml solution for injection pre-filled disposable devices

- Golimumab 50mg/0.5ml solution for injection pre-filled disposable devices

- Golimumab 50mg/0.5ml solution for injection pre-filled syringes

- Lanreotide 120mg/0.5ml solution for injection pre-filled syringes

- Lanreotide 90mg/0.5ml solution for injection pre-filled syringes

- Lanreotide 60mg/0.5ml solution for injection pre-filled syringes

- Mesalazine 1.5g gastro-resistant modified-release granules sachets sugar free

- Mesalazine 1.6g gastro-resistant tablets

- Mesalazine 1g gastro-resistant modified-release granules sachets sugar free

- Mesalazine 1g modified-release granules sachets sugar free

- Mesalazine 1g modified-release tablets

- Mesalazine 1g suppositories

- Mesalazine 1g/100ml enema

- Mesalazine 1g/application foam enema

- Mesalazine 250mg gastro-resistant tablets

- Mesalazine 2g modified-release granules sachets sugar free

- Mesalazine 2g/59ml enema

- Mesalazine 400mg gastro-resistant tablets

- Mesalazine 4g modified-release granules sachets sugar free

- Mesalazine 500mg gastro-resistant modified-release granules sachets sugar free

- Mesalazine 500mg gastro-resistant tablets

- Mesalazine 500mg suppositories

- Mesalazine 800mg gastro-resistant tablets

- Nilotinib 150mg capsules

- Nilotinib 200mg capsules

- Nilotinib 50mg capsules

- Nintedanib 100mg capsules

- Nintedanib 150mg capsules

- Omalizumab 150mg/1ml solution for injection pre-filled syringes

- Omalizumab 75mg/0.5ml solution for injection pre-filled syringes

- Omalizumab 300mg/2ml solution for injection pre-filled disposable devices

- Omalizumab 300mg/2ml solution for injection pre-filled syringes

- Pazopanib 200mg tablets

- Pazopanib 400mg tablets

- Perampanel 10mg tablets

- Perampanel 12mg tablets

- Perampanel 2mg tablets

- Perampanel 4mg tablets

- Perampanel 500micrograms/ml oral suspension sugar free

- Perampanel 6mg tablets

- Perampanel 8mg tablets

- Pertuzumab 420mg/14ml solution for infusion vials 1 vial

- Testosterone undecanoate 1g/4ml solution for injection ampoules

- Testosterone undecanoate 1g/4ml solution for injection vials

- Ticagrelor 60mg tablets

- Ticagrelor 90mg orodispersible tablets sugar free

- Ticagrelor 90mg tablets

- Tocilizumab 162mg/0.9ml solution for injection pre-filled disposable devices

- Tocilizumab 162mg/0.9ml solution for injection pre-filled syringes

- Tocilizumab 200mg/10ml solution for infusion vials

- Tocilizumab 400mg/20ml solution for infusion vials

- Tocilizumab 80mg/4ml solution for infusion vials

- Trabectedin 1mg powder for solution for infusion vials

- Trabectedin 250microgram powder for solution for infusion vials

II.1.5) Cyfanswm gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 131 244 104.00 GBP

II.1.6) Gwybodaeth am lotiau

Mae’r contract hwn wedi’i rannu’n lotiau: Ydy

II.2) Disgrifiad

Rhif y Lot 1

II.2.1) Teitl

Cytokine Modulators

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of cytokine modulators to NHS Scotland. The Authority intends to award this Lot as an unranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

Rhif y Lot 2

II.2.1) Teitl

Gastrointestinal, Endocrine, Nutrition, Blood, and Multiple Sclerosis Medicines

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of gastrointestinal, endocrine, nutrition, blood, and multiple sclerosis medicines NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

Rhif y Lot 3

II.2.1) Teitl

Denosumab (osteoporosis)

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of denosumab (osteoporosis) to NHS Scotland. The Authority intends to award this Lot as an unranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

Rhif y Lot 4

II.2.1) Teitl

Apremilast

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of apremilast to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

Rhif y Lot 5

II.2.1) Teitl

Cardiovascular and Respiratory Medicines

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of cardiovascular and respiratory medicines to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

Rhif y Lot 6

II.2.1) Teitl

Nintedanib

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of nintedanib to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

Rhif y Lot 7

II.2.1) Teitl

Cancer Medicines (Group 1)

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of cancer medicines (Group 1) to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

Rhif y Lot 8

II.2.1) Teitl

Cancer Medicines (Group 2)

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of cancer medicines (Group 2) to NHS Scotland. The Authority intends to award this Lot as an unranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

Rhif y Lot 9

II.2.1) Teitl

Neurology Medicines

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of neurology medicines to NHS Scotland. The Authority intends to award this Lot as a ranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

II.3) Dyddiad amcangyfrifedig ar gyfer cyhoeddi’r hysbysiad contract:

15/08/2025

Section IV: Gweithdrefn

IV.1) Disgrifiad

IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)

The procurement is covered by the Government Procurement Agreement: Ydy

Section VI: Gwybodaeth ategol

VI.3) Gwybodaeth ychwanegol

The estimated values referred to in Section II.1.5 cover maximum forty-eight (48) month duration of the Framework Agreement (comprised of the initial duration and any extension duration(s) combined).

NOTE: To register your interest in this notice and obtain any additional information please visit the Public Contracts Scotland Web Site at https://www.publiccontractsscotland.gov.uk/Search/Search_Switch.aspx?ID=801883.

(SC Ref:801883)

VI.5) Dyddiad anfon yr hysbysiad hwn

05/08/2025

Codio

Categorïau nwyddau

ID Teitl Prif gategori
33600000 Cynhyrchion fferyllol Cyfarpar meddygol, deunydd fferyllol a chynhyrchion gofal personol

Lleoliadau Dosbarthu

ID Disgrifiad
100 DU - I gyd

Cyfyngiadau Rhanbarthol ar y Rhybuddion

Mae’r prynwr wedi cyfyngu’r rhybuddion ar gyfer yr hysbysiad hwn i gyflenwyr yn y rhanbarthau canlynol.

ID Disgrifiad
Nid oes cyfyngiadau ar y rhybuddion ar gyfer yr hysbysiad hwn.

Ynglŷn â'r prynwr

Prif gyswllt:
cameron.wright@nhs.scot
Cyswllt gweinyddol:
N/a
Cyswllt technegol:
N/a
Cyswllt arall:
N/a

Gwybodaeth bellach

Dyddiad Manylion
Nid oes unrhyw wybodaeth bellach wedi'i lanlwytho.

0800 222 9004

Mae'r llinellau ar agor rhwng 8:30am a 5pm o ddydd Llun i ddydd Gwener.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.